split-banner-image

TEXT

Closed

IBCSG 25-02/BIG 3-02: TEXT

BCT Study Chair:

Prue Francis

A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.

international

2423

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

249

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

24

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

TEXT PUBLICATIONS

2025

Assessment of ovarian function suppression (OFS)-containing adjuvant endocrine therapy in premenopausal women by Breast Cancer Index.

O’Regan R, Ren Y, Zhang Y, Siuliukina N, Schnabel CA, Kammler R, Viale G, Dell’Orto P, Panagi O, Walley B, Fleming GF, Francis PA, Loi S, Colleoni M, Treuner K, Regan MM. Journal of Clinical Oncology. 2025; 43(16 suppl).:ASCO Abs557. DOI: 10.1200/JCO.2025.43.16_suppl.557, Abstract

15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.

Francis PA, Fleming GF, Pagani O, Walley B, Loi S, Colleoni M, Regan MM, on behalf of SOFT and TEXT Investigators, IBCSG, BIG and North American BC Groups. Journal of Clinical Oncology. 2025; 43(16 suppl):ASCO Abs505. DOI: 10.1200/JCO.2025.43.16_suppl.505, Presentation

2024

Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials.

Pan H, Gray R, on behalf of the EBCTCG. Journal of Clinical Oncology. 2024; 32:5s(SABCS 2024), [Abstract Number SESS-1911; GS2-09], Abstract

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.

Early Breast Cancer Trialists’ Collaborative Group. The Lancet. 2024; 4041407-18, epub 12 October 2024, E-pub

2022

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials.

Pagani* O, Walley* BA, Francis GF, Colleoni M, Láng I, Gomez Hl, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winder EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan** MM, Francis** PA, for the SOFT and TEXT Investigators and the International Breast Cancer Study Group. *Co-lead authors. **Co-last authors. Journal of Clinical Oncology. 2022; Epub 15 December 2022. doi: 10.1200/JCO.22.01064, E-pub

Back to the Beginning: The role of ovarian suppression in management of hormone sensitive breast cancer in premenopausal women.

Connolly RM, Miller RD. Journal of Clinical Oncology. 2022; epub 15 December 2022 doi: 10.1200/JCO.22.02319., Editorial

LOAD MORE

Institutions